Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, August 20, 2020
Humanetics and Pii will work together to support a clinical trial of BIO 300 in COVID-19 patients.
read more
ANA and Quotient Sciences announced a partnership to support the manufacturing of ANA001 as a potential treatment for COVID-19.
read more
Headlands Research announced its research centers have been selected to participate in AstraZeneca’s upcoming Phase III COVID-19 vaccine trial.
read more
Wednesday, August 05, 2020
The FDA proposed to include four bulk drug substances on the list of bulk drug substances that outsourcing facilities may use in drug compounding consistent with section 503B of the Federal Food, Drug & Cosmetic Act.
read more
Sandoz has announced plans for a joint investment, together with the Austrian federal government, to strengthen the long-term future of integrated antibiotics manufacturing in Europe.
read more
LGM Pharma has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma.
read more
To reduce the risk of death from opioid overdose, the FDA is making the following recommendations about the opioid reversal medicine, naloxone.
read more
Granules voluntarily recalling 12 lots of Metformin Hydrochloride Extended-Release Tablets due to the detection of NDMA levels above the Acceptable Daily Intake Limit.
read more
Cipla has received final approval for its ANDA for Icatibant Injectable 30mg/3mL from the FDA.
read more
The FDA has been determining the safest and most appropriate time to resume prioritized domestic inspections of FDA-regulated facilities and other associated activities since we first announced postponement in March.
read more
Orchard Therapeutics and MolMed have extended their collaboration – initiated in April 2018 – for a period of five years through June 2025.
read more
Lonza announced the establishment of a Center of Excellence for Dry Powder Inhaler drug product development at its OR site.
read more
Vetter and Rentschler Biopharma have announced their strategic collaboration, to enhance their services and offer complementary skills and experience along the biopharmaceutical value chain.
read more
Artelo Biosciences has expanded its existing research and worldwide commercial license agreement with The Research Foundation For The State University of New York, Stony Brook.
read more
Catalent has signed an agreement with ViralClear to work on the development of a potential treatment for adults with advanced COVID-19.
read more